C Stock Recent News

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive eq

Citigroup's (C) cost-cutting measures, technology modernization, and strategic exits have led to tangible improvements, positioning it as a "buy" despite macroeconomic challenges. C's strong CET1 and PCR metrics, along with a conservative loan-to-deposit ratio, indicate financial stability and resilience compared to competitors. Trading at a forward P/E of 9.3x, C is reasonably priced with potential for a rally to $80, supported by technical indicators.

In the most recent trading session, Citigroup (C) closed at $70.99, indicating a +0.94% shift from the previous trading day.

Sandy Weill on Thursday announced a new $50 million donation to create a cancer research and treatment hub focused on immunotherapy. The hub is in partnership with four leading research institutions.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Citigroup (C) have what it takes?

In the latest trading session, Citigroup (C) closed at $74.47, marking a +0.58% move from the previous day.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The S&P 500 index (^GSPC 0.08%) quickly fell into correction territory not too long ago. Dropping alongside the index were the shares of Citigroup (C 0.17%).

Citigroup (C) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Fed raises the inflation target and cuts growth projections due to Trump's tariffs, dimming the outlook for banks like JPM, BAC, C, CMA and KEY.